Satraplatin is a prescription medication used to treat prostate cancer that has spread to other parts of the body. It is taken as a pill and helps to reduce the size of tumors and slow the growth of cancer cells. Satraplatin works by blocking certain proteins in the body that can cause cancer cells to grow and divide. It is usually used in combination with another medication called prednisone to help reduce the side effects.
Satraplatin is a medication that has been investigated as a potential treatment for cancer, but it is not currently approved for use by the U.S. Food and Drug Administration (FDA) or many other regulatory bodies. Here's a breakdown of what we know about Satraplatin:
Type of Drug:
- Platinum-Based Antineoplastic Agent: Satraplatin belongs to a class of drugs called platinum-based chemotherapeutic agents. These medications work by damaging the DNA of cancer cells, preventing them from dividing and growing.
Investigated Use:
- Prostate Cancer: The primary focus of research on Satraplatin has been for the treatment of castration-resistant prostate cancer, a type of prostate cancer that has progressed despite hormone therapy [Wikipedia].
- Other Cancers: There has also been some investigation into the use of Satraplatin for other cancers, such as lung cancer and ovarian cancer, but these studies are not as extensive [National Cancer Institute].
Delivery Method:
- Orally Administered: One of the key features of Satraplatin is that it was designed to be taken orally. This is in contrast to other platinum-based chemotherapy drugs, which are typically administered intravenously (through a vein).
Outcomes of Investigations:
- Limited Success: While Satraplatin showed some initial promise in preclinical studies and early clinical trials, larger studies did not demonstrate significant overall benefits compared to existing treatments, and it was not approved for use [National Cancer Institute].
Current Status:
- Not Available: Satraplatin is not currently commercially available and is not being actively pursued for development by any major pharmaceutical companies.
Important Considerations:
- Not a Treatment Option: Due to its lack of approval and limited success in trials, Satraplatin is not a recommended treatment option for any type of cancer.